Adaptive Biotechnologies Corp
ADPT
42 insider filings · Latest: Apr 27, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Mar 10 12:29 AM | Francis LOChief People Officer | Sale | 38,074 | $15.09 | $574.5K | 321,967(D) | View → |
| Mar 3, 2026 | Mar 6 1:05 AM | Michelle Renee GriffinDirector | Sale | 48,044 | $15.30 | $735.1K | 15,394(D) | View → |
| Mar 5, 2026 | Mar 6 12:42 AM | Julie RubinsteinPresident and COO | Sale | 30,941 | $16.00 | $495.1K | 575,235(D) | View → |
| Mar 4, 2026 | Mar 6 12:42 AM | Julie RubinsteinPresident and COO | Sale | 30,941 | $16.60 | $513.6K | 579,573(D) | View → |
| Mar 3, 2026 | Mar 6 12:42 AM | Julie RubinsteinPresident and COO | Sale | 30,941 | $15.67 | $484.8K | 583,911(D) | View → |
| Mar 3, 2026 | Mar 5 12:58 AM | Harlan S RobinsChief Scientific Officer | Sale | 14,233 | $16.52 | $235.1K | 1,155,291(D) | View → |
| Mar 2, 2026 | Mar 5 12:58 AM | Harlan S RobinsChief Scientific Officer | Sale | 10,000 | $15.72 | $157.2K | 1,169,524(D) | View → |
| Mar 3, 2026 | Mar 4 12:51 AM | Chad M RobinsDirector, CEO and Chairman | Sale | 53,083 | $15.52 | $823.8K | 1,934,247(D) | View → |
| Mar 2, 2026 | Mar 4 12:51 AM | Chad M RobinsDirector, CEO and Chairman | Sale | 289,024 | $15.82 | $4.6M | 1,987,330(D) | View → |
| Feb 27, 2026 | Mar 4 12:51 AM | Chad M RobinsDirector, CEO and Chairman | Sale | 182,891 | $15.99 | $2.9M | 2,276,354(D) | View → |
| Mar 3, 2026 | Mar 3 9:59 PM | Harlan Robins | Proposed Sale | 14,233 | $16.08 | $228.9K | — | View → |
| Mar 3, 2026 | Mar 3 9:59 PM | Chad Robins | Proposed Sale | 53,083 | $16.08 | $853.6K | — | View → |
| Mar 3, 2026 | Mar 3 9:50 PM | JULIE RUBINSTEIN | Proposed Sale | 1,206,661 | $16.12 | $19.5M | — | View → |
| Mar 3, 2026 | Mar 3 9:50 PM | MICHELLE GRIFFIN | Proposed Sale | 48,044 | $16.12 | $774.5K | — | View → |
| Mar 2, 2026 | Mar 2 10:24 PM | Harlan Robins | Proposed Sale | 10,000 | $16.12 | $161.2K | — | View → |
| Mar 2, 2026 | Mar 2 10:24 PM | Chad Robins | Proposed Sale | 289,024 | $16.12 | $4.7M | — | View → |
| Feb 27, 2026 | Feb 27 9:47 PM | Chad Robins | Proposed Sale | 182,891 | $16.02 | $2.9M | — | View → |
| Feb 4, 2026 | Feb 7 12:30 AM | Kyle PiskelChief Financial Officer | Sale | 2,145 | $18.46 | $39.6K | 216,637(D) | View → |
| Feb 3, 2026 | Feb 5 12:48 AM | Harlan S RobinsChief Scientific Officer | Sale | 8,120 | $19.00 | $154.3K | 1,179,524(D) | View → |
| Feb 2, 2026 | Feb 5 12:48 AM | Harlan S RobinsChief Scientific Officer | Sale | 34,668 | $18.60 | $644.8K | 1,187,644(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Mar 6 12:42 AM | Julie RubinsteinPresident and COO | Option Exercise | 26,603 | $12.14 | 451,463(D) | View → |
| Feb 4, 2026 | Feb 7 12:30 AM | Kyle PiskelChief Financial Officer | Option Exercise | 2,145 | $12.14 | 2,146(D) | View → |
← Previous
Page 3 of 3